Verona Pharma (VRP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

41.50p
   
  • Change Today:
    -2.00p
  • 52 Week High: 106.00
  • 52 Week Low: 39.60
  • Currency: UK Pounds
  • Shares Issued: 105.33m
  • Volume: 34,644
  • Market Cap: 43.71m
  • RiskGrade: 173

Verona Pharma Overview

Verona Pharma is developing first in class drugs to treat respiratory disease such as COPD asthma and chronic severe cough

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 0.7  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Verona Pharma Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-14 n/a (3.76) (16.00)p n/a n/a n/a n/a 0.0%
31-Dec-15 n/a (9.00) (1,855.00)p n/a n/a n/a n/a 0.0%
31-Dec-16 n/a (5.97) (750.00)p n/a n/a n/a n/a 0.0%
31-Dec-17 n/a (25.20) (23.40) n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (24.13) (18.90) n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Verona Pharma Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 n/a (42.96) (33.48)p n/a n/a n/a n/a 0.0%
31-Dec-20 8.33 (49.79) (32.71)p n/a n/a n/a n/a 0.0%

Copyright © 2019 FactSet Research Systems Inc. All rights reserved.

Verona Pharma Company Announcements

Holding(s) in Company TR-1: Standard form for no... 28-Nov-2019 10:25 GlobeNewswire NA
Verona Pharma plc: Grant of Options to PDMR 27-Nov-2019 07:00 GlobeNewswire NA
Verona Pharma plc: PDMR Dealing – Purchase... 18-Nov-2019 07:00 GlobeNewswire NA

Latest Verona Pharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Verona Pharma Market Data

Currency UK Pounds
Share Price 41.50p
Change Today -2.00p
% Change -4.60 %
52 Week High 106.00
52 Week Low 39.60
Volume 34,644
Shares Issued 105.33m
Market Cap 43.71m
RiskGrade 173

Verona Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.12% above the market average22.12% above the market average22.12% above the market average22.12% above the market average22.12% above the market average
62.71% above the sector average62.71% above the sector average62.71% above the sector average62.71% above the sector average62.71% above the sector average
Price Trend
84.34% below the market average84.34% below the market average84.34% below the market average84.34% below the market average84.34% below the market average
52.54% below the sector average52.54% below the sector average52.54% below the sector average52.54% below the sector average52.54% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 5
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Verona Pharma Dividends

No dividends found

Trades for 06-Dec-2019

Time Volume / Share Price
16:26 2,390 @ 41.49p
16:25 12,051 @ 41.49p
14:59 10,000 @ 40.00p
13:25 43 @ 41.02p
12:58 7,122 @ 41.98p

Verona Pharma Key Personnel

CEO Sven Jan-Anders Karlsson
CFO Piers Morgan

Top of Page